TheratechnologiesTHTX
About: Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
Employees: 103
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
1.24% more ownership
Funds ownership: 35.95% [Q1] → 37.19% (+1.24%) [Q2]
0% more funds holding
Funds holding: 34 [Q1] → 34 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
12% less capital invested
Capital invested by funds: $27.3M [Q1] → $24M (-$3.39M) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for THTX.
Financial journalist opinion
Based on 6 articles about THTX published over the past 30 days
